TP53 and acute myeloid leukemia: The somatic mutations and genomic loss of TP53 due to deletions of the 17p chromosome occur in 5–10% of de novo AML cases [117] and in 40% of patients with adverse-risk cytogenetics and treatment-related myeloid neoplasms [118] and are associated with poor prognosis [119].